NasdaqGS:REGNBiotechs
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Japan’s New Dupixent Approval
Regeneron Pharmaceuticals (REGN) is back in focus after Japan’s Ministry of Health, Labour and Welfare approved Dupixent for adults with moderate to severe bullous pemphigoid, expanding the drug’s footprint in a rare inflammatory skin disease.
See our latest analysis for Regeneron Pharmaceuticals.
Even with the positive Dupixent news, Regeneron’s short term share price return has been muted. The 7 day share price return is 0.66% and the 30 day share price return reflects a 5.62% decline. The...